Street View: Brokerages see Abbott's growth picking up later in 2026

Abbott ABT.N forecast first-quarter profit below estimates after missing Wall Street expectations for quarterly revenue on Thursday, hurt by weakness in its nutrition and diagnostics businesses

On average, 31 analysts rate the stock a "buy"; median PT $137.50, per LSEG data

EYES ON 2H'26 AS CATALYSTS UNFOLD

Piper Sandler ("overweight," PT: $135) says "we still like the set-up for FY2026 behind a couple of key product launches, the ongoing momentum in the medtech business, and with the headwinds in the diagnostics business set to largely abate"

RBC Capital Markets ("outperform," PT: $135) says ABT is poised for growth acceleration, but into 2H'26, aided by product launches and ramp and waning headwinds in diagnostics and nutrition

TD Cowen ("buy," PT: $137) says "we are constructive and see a near-term opportunity, as we expect ABT to benefit from its usual drivers in 2026 while diagnostics and nutrition headwinds shrink"

Evercore ISI ("outperform," PT: $138) says rough days are understandable given miss, but growth levers remain intact into 2H26/FY27